Lento Bio
Phase 3Developing a first-in-class eye drop to reverse presbyopia — the age-related loss of near vision that affects 1.8 billion people worldwide.
Founded
2020
Focus
Small Molecules
About
Developing a first-in-class eye drop to reverse presbyopia — the age-related loss of near vision that affects 1.8 billion people worldwide.
Funding History
1Total raised: $3.5M
Seed$3.5MUndisclosedFeb 15, 2023
Company Info
TypePrivate
Founded2020
LocationSan Diego, United States
StagePhase 3
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile